CAPN13

Across TCGA pan-cancer cohorts, CAPN13 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CAPN13 data layer compared with 24 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in adrenocortical carcinoma (ACC), where higher CAPN13 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CAPN13 expression acts as an unfavorable survival marker, although some lineages such as SKCM and UCEC show a favorable association.

ACC, COAD, and LIHC are the cancer types where CAPN13 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ACC	OS	Median	All	0.145	0.888	<.001	45	view →
COAD	OS	Median	II,III,IV	0.111	0.853	<.001	12	view →
LIHC	DFS	Median	All	0.311	0.557	.026	3	view →
SKCM	DFS	Median	III,IV	0.658	0.454	.045	3	view →
UCEC	DFS	Median	II,III,IV	0.874	0.434	.035	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

CAPN13–ACC (OS)

Open the ACC breakdown →